Benign eccrine breast spiradenoma

Summary

Benign eccrine breast spiradenoma (MONDO:0002055) is a disease. A subtype of breast benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign eccrine breast spiradenoma
Mondo ID	MONDO:0002055
DOID	DOID:1616
NCIT	C5193
UMLS	C1332492
MedGen	231933
GARD	0027596
Is cancer (heuristic)	no

Also known as: benign breast eccrine spiradenoma · benign eccrine breast spiradenoma · benign eccrine spiradenoma of breast · benign eccrine spiradenoma of the breast

Disease family

This is a subtype of breast benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › thoracic benign neoplasm › breast benign neoplasm › benign eccrine breast spiradenoma

Related subtypes (14): breast lipoma, breast cyst, breast fibroadenoma, breast leiomyoma, breast adenoma, breast myofibroblastoma, benign breast adenomyoepithelioma, breast hemangioma, multiple fibroadenoma of the breast, benign breast phyllodes tumor, intraductal breast papilloma, benign neoplasm of male breast, diabetic mastopathy, lymphocytic mastitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.